Screener
Amgen AMGN Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $10.05B+9.5% | $8.62B+5.8% | $9.87B+8.6% | $9.56B+12.4% | $9.18B+9.4% | ||
| $2.81B-6.6% | $2.74B-7.5% | $2.98B-4.4% | $3.08B-6.9% | $3.01B-7.0% | ||
| $7.24B+17.4% | $5.87B+13.4% | $6.89B+15.3% | $6.48B+24.7% | $6.17B+19.7% | ||
| 72%+4.8pp | 68.2%+4.6pp | 69.8%+4.1pp | 67.8%+6.7pp | 67.2%+5.8pp | ||
| $1.87B+7.1% | $1.72B+15.7% | $2.14B+24.2% | $1.9B+31.0% | $1.74B+20.5% | ||
| $1.75B+3.2% | $1.6B-5.0% | $1.95B+3.9% | $1.72B+5.8% | $1.69B-5.3% | ||
| $6.54B+0.3% | $5.95B-14.6% | $7.15B+5.5% | $7.03B+8.9% | $6.52B+0.7% | ||
| $3.51B+32.3% | $2.67B+126% | $2.72B+17.7% | $2.53B+23.4% | $2.66B+39.1% | ||
| 35%+6.0pp | 30.9%+16.5pp | 27.6%+2.1pp | 26.4%+2.4pp | 28.9%+6.2pp | ||
| $673M-3.0% | $657M-9.1% | $653M-12.6% | $685M-11.7% | $694M-14.1% | ||
| -$73M+81.5% | $75M-95.1% | —— | $2.08B+13.7% | -$394M-28.3% | ||
| $2.77B+76.5% | $2.08B+5.6% | $1.51B+93.6% | $3.92B+26.4% | $1.57B+97.5% | ||
| $393M+189% | $265M+9.1% | $181M+16.8% | $705M+160% | $136M+183% | ||
| $2.38B+65.9% | $1.82B+5.1% | $1.33B+113% | $3.22B+13.6% | $1.43B+92.0% | ||
| 23.6%+8.0pp | 21.1%-0.1pp | 13.5%+6.6pp | 33.7%+0.4pp | 15.6%+6.7pp | ||
| $4.37+64.9% | $3.34+4.4% | $2.46+112% | $5.93+13.6% | $2.65+92.0% | ||
| $4.63B+15.7% | $3.78B+47.4% | $3.85B+3.9% | $3.83B+11.3% | $4B+20.8% | ||
| 46%+2.5pp | 43.9%+12.4pp | 39%-1.8pp | 40.1%-0.4pp | 43.5%+4.1pp | ||
| $3.51B+32.3% | $2.67B+126% | $2.72B+17.7% | $2.53B+23.4% | $2.66B+39.1% |
FAQ
- What is Amgen's revenue?
- Amgen (AMGN) generated $38.1B in revenue over the trailing twelve months, up 9.1% year over year.
- Is Amgen profitable?
- Amgen reported $8.7B in net income over the trailing twelve months, a 23.0% net margin.
- What are Amgen's profit margins?
- Gross margin is 69.5% and operating margin is 30.0%, with a 23.0% net margin.
- What is Amgen's earnings per share?
- Amgen's diluted EPS over the trailing twelve months is $16.10.
- Where does Amgen's income statement data come from?
- Every line is extracted from Amgen's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
